Welcome to the July issue of The Pharmafile Brief, where we explore critical topics shaping healthcare today. In our debut issue, we highlight the advances in cancer treatments, and also delve into the latest in dermatology, from UV safety awareness to breakthrough treatments for rare skin conditions. We also showcase the transformative role of healthcare branding in building trust and engagement as we bring together the innovations and challenges defining the sector, with insights on NHS reforms, market access strategies and the intersection of design and purpose.
In one of the highlights of this issue, we talk to Chris Ehrlich, CEO of CERo therapeutics, about T-cell therapy: its origins, how it works and what Chris envisions for the future of this form of immunotherapy. Chris talks about how antibody drug conjugates passively treated cancer, leading scientists to consider what would happen if patients were treated actively. What if the most powerful therapeutic human beings have was used – their own immune system – and if that immune system could be trained to fight cancer.Â

Branding expert Ged Equi examines how companies sustain iconic brands through consistent strategy while evolving to showcase people and purpose. Branding in healthcare is shifting beyond logos to focus on attracting talent, engaging patients and building trust, and future branding will centre on values like inclusion, well-being and meaningful purpose.

The issue also includes an insightful article from Theramex, which spotlights the chronic neglect of endometriosis in the UK. With dismissal from healthcare professionals, diagnosis delays, clear racial disparities and reduced funding targets, it stresses the need to treat gynaecological pain with greater urgency and seriousness.

From 11-12 June, over 9,000 attendees gathered in Manchester for the NHS ConfedExpo to discuss the future of UK healthcare, underscoring the power of collaboration in driving system-wide transformation. PMGroup is proud to have launched the 2026 Excellence in Healthcare Partnerships (EHP) Awards at the Expo, reinforcing the sector’s commitment to measurable impact through cross-sector collaboration.


Pharmafile is pleased to present the first in a new series: the Gateway to Local Adoption from Visions4Health, a market access consultancy, which brings together perspectives from local UK healthcare professionals, offering in-depth analysis of key challenges and applicable insights for the sector. Nick Merrifield, a GP based in Kingston-upon-Thames, explores the evolving concept of neighbourhood working in the NHS and the increasing push to shift care from hospitals to communities. Also, Graham Duce, Integrated Care Board GP prescribing and clinical lead, discusses the importance of medicines operations teams in the new ICB structures.


Visions4Health positions itself as a key partner for life sciences companies facing complex UK market access, as the healthcare system shifts toward preventative, digital, and community care. With NHS reforms and regional disparities, a one-size-fits-all approach no longer works. By combining stakeholder engagement with practical solutions, the company helps clients achieve meaningful adoption.
We continue the Pharmafocus Five Facts series by reporting Five Facts about UV exposure and sun safety , in time for UV Safety Awareness Month in July, discussing cautionary action taken by the World Health Organisation against skin cancer to the relationship between sunburn and the incidence of melanoma.Â
June saw numerous developments in dermatological treatments. LEO Pharma is investigating delgocitinib in palmoplantar pustulosis, a chronic inflammatory skin condition. Sanofi and Regenron reported a positive impact of Dupixent (dupilumab) in patients with atopic dermatitis and Fitzpatrick skin types IV-VI. Towards the end of the month, Galderma stated it will trial nemolizumab in systemic sclerosis and chronic pruritus of unknown origin. Additionally, NICE recommended Spevigo (spesolimab) for generalised pustular psoriasis.
In other news, Brenntag Specialties acquired Czech-based mcePharma, strengthening its position in the pharma industry. Celltrion opened its new UK headquarters, indicating its ongoing commitment to the UK healthcare market. Regarding mental health, Otsuka and Click Therapeutics launched an app in the UK for major depressive disorder, for use alongside existing treatments.
Furthermore, we reported on several strategic moves. Cancer Research UK has announced the appointment of Samra Turajlić as the new director of its Manchester base. As part of wider leadership transformation, LEO pharma appointed Helle Hedegaard Juhl as EVP of global people & corporate affairs, and German dermatology company, Mallia Innovations, added three new advisors to its board.
We hope you enjoy reading this issue of The Pharmafile Brief! Look out for a new issue at the beginning of each month, with more in depth analysis of the pharma, biotech and healthcare industry.

Published on July 7th, 2025

Published on July 7th, 2025

Published on July 7th, 2025

Published on July 7th, 2025

Published on July 7th, 2025

Published on July 7th, 2025

Published on July 4th, 2025

Published on June 27th, 2025

Published on June 27th, 2025

Published on June 27th, 2025

Published on June 20th, 2025

Published on June 19th, 2025

Published on June 18th, 2025

Published on June 17th, 2025

Published on June 11th, 2025

Published on June 5th, 2025

Published on June 3rd, 2025